Comparative Pharmacology
Head-to-head clinical analysis: TRISENOX versus XOSPATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRISENOX versus XOSPATA.
TRISENOX vs XOSPATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells by targeting the PML-RARα fusion protein, leading to its degradation and subsequent differentiation and apoptosis. It also generates reactive oxygen species, disrupts mitochondrial function, and activates caspases.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
0.15 mg/kg IV daily until bone marrow remission, then 0.15 mg/kg IV 5 days/week for 2 weeks with 2 weeks off for up to 6 cycles.
120 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life for inorganic arsenic is approximately 10-14 hours, with a mean of 12 hours. The methylated metabolites have longer half-lives, contributing to accumulation with repeated dosing. Clinical context: Supports daily dosing schedule with monitoring for toxicity.
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Primarily renal excretion of unchanged arsenic (approximately 15-30% of the dose within 24 hours) with the remainder undergoing hepatic methylation to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), which are excreted renally. Biliary and fecal elimination are minor (<5%).
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Category C
Category C
Antineoplastic, Arsenic Trioxide
Antineoplastic